Depression and pregnancy: Use of selective serotonin reuptake inhibitors in pregnancy

McConnell, Peter J.; Linn, Kathy; Filkins, Karen

doi:10.1016/s1068-607x(97)00116-9

Cited by 6 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…sertraline. fluoxetine and fluvoxamine (31,32,33). As yet, there are no studies examining the safety profile of escitalopram (Lexapro^; citalopram's recently introduced enantiomer) in pregnancy, although it is classified as category C by the FDA.…”

Section: Selective Serotonin Reiiptiike Inhibitors (Ssris)mentioning

confidence: 99%

Pharmacotherapy of Depression in Pregnancy

Patkar¹,

Bilal²,

Masand³

2004

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

About 20% of pregnant women experience clinical depression. Inadequate treatment of depression has been associated with adverse outcomes in the mother as well as the newborn. Clinicians are often uncertain about pharmacological interventions to treat depressed pregnant women due to concerns regarding fetal exposure to medications. Moreover newer antidepressants with different pharmacological profiles and little data on fetal risk continue to be introduced at a brisk pace. Accumulating data from pharmaceutical registries, cohort studies, toxicology centers, some prospective studies, and case series have permitted certain guidelines for antidepressant use during pregnancy. We review the safety profiles of commonly used antidepressants, discuss clinical decision making based on risk-benefit considerations and make recommendations for pharmacological treatment of depressed women during pregnancy.

show abstract

Section: Selective Serotonin Reiiptiike Inhibitors (Ssris)mentioning

confidence: 99%

Pharmacotherapy of Depression in Pregnancy

Patkar¹,

Bilal²,

Masand³

2004

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

show abstract

A review of the safety of selective serotonin reuptake inhibitors during pregnancy

Goldstein

Sundell

1999

Hum. Psychopharmacol. Clin. Exp.

View full text Add to dashboard Cite

Antidepressant treatment may be desirable or necessary during pregnancy; however, the bene®t of treatment must balance the bene®ts to the mother with any risk to the developing fetus. In order to make educated, patient-speci®c, bene®t-to-risk assessments, an understanding of possible risks associated with in-utero antidepressant exposure is important. We reviewed all published cohort-controlled studies (n 4) and prospective surveys (n 5) regarding SSRI use in pregnancy. Outcomes from over 1000¯uoxetine-exposed pregnancies, more than for any other antidepressant, indicate that ®rst trimester¯uoxetine exposure does not statistically signi®cantly increase risk for spontaneous abortion or major malformation. Outcomes from nearly 300 pregnancies exposed to another SSRI (sertraline, paroxetine, or¯uvoxamine) suggest the same conclusion. Following in-utero SSRI exposure, birthweight, rates of prematurity, and postnatal complications appear similar to control values. Preschool age children exposed tō uoxetine in-utero show no signi®cant dierences from controls in global IQ, language, or behavior; such long-term data are not available for other SSRIs. The substantial clinical experience with¯uoxetine-exposed pregnancies and the preliminary data regarding other SSRIs is reassuring when considering depression treatment for women of childbearing potential.

show abstract